Mosquitoes as anti-malaria 'syringes'?

German scientists propose combination of natural exposure and antibiotics to create new vaccine

Eisha Sarkar

Posted On Saturday, September 04, 2010   

A needle-free malaria vaccine with a 'buzz' is what German scientists have discovered by combining antibiotics with malaria-infected mosquitoes and effectively using mosquitoes themselves as 'syringes.'

If successful, this new treatment could dramatically reduce the nearly one million deaths caused from malaria every year. The treatment is not aimed at travellers, because it protects against the disease once it is already contracted, but has positive implications for those living in endemic areas.

Rather than attempting to protect against all mosquito bites like malaria prevention methods such as the utilisation of bed nets, this treatment uses the infection as part of the solution in combination with antibiotics.

The idea behind the study was to combine antibiotic treatment (that travellers use to protect themselves against malaria) with a natural exposure. Scientist Kai Matuschewski and his research team from Max Planck Institute for Infection Biology in Berlin infected mice with sporozoites released from the malaria-carrying mosquitoes. The sporozoites migrated to the liver where they replicated abundantly and matured to the disease-causing blood stage cells called merozoites.

However, in this study, although the merozoites continued to develop in the liver, the antibiotics prevented them from actually entering red blood cells, which disabled the onset of malaria symptoms. "The mosquito is our sort of syringe that delivers the pathogen and we stop the parasite from growing in the liver through antibiotic prophylaxis," Dr Matuschewski is reported to have noted.

Not only did the mice not get sick from this treatment, but subsequent trials that eventually did not include the addition of antibiotics revealed that the mice developed long-term immunity. The antibiotics used in the study were clindamycin and azithromycin, both generic drugs that are cheap and readily available.

Due to the availability of the generic drugs, Matuschewski and his research team are hopeful that clinical trials can begin in sub-Saharan Africa by the start of next summer. While the findings are promising, scientists are careful to point out that their research constitutes just one component of the many factors needed to fight the disease and end deaths from malaria.

Malaria vaccine for India

Scientists such as Chetan Chitnis from the International Centre for Genetic Engineering and Biotechnology (ICGEB) at Delhi along with his team are trying hard to make the vaccine against malaria reach the phase I trial at the earliest. It would be another five to seven years before the vaccine would reach markets, he is reported to have said.

Plasmodium, the malarial parasite, is a difficult organism to work with for various reasons, including fast mutations. But scientists have managed to pick up the gene sequence, which does not change with mutation and have made the vaccine work at the laboratory scale for both plasmodium vivax and falciparum.

It has taken 34 years for scientists to design the malaria vaccine, which has worked well on mice and monkeys with good efficacy.

Pic: Gabor Bibor



Rate me....

   Mail this articleMail this article    Print this articlePrint this article

Share Share Reddit.com Share del.icio.us Share StumbleUpon.com


Quote of the day

A bad cold wouldn't be so annoying if it weren't for the advice of our friends. – Kin Hubbard